Expression of THOP1 and Its Relationship to Prognosis in Non-Small Cell Lung CancerReportar como inadecuado

Expression of THOP1 and Its Relationship to Prognosis in Non-Small Cell Lung Cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.


The study was designed to detect the expression level of thimet oligopeptidase THOP1 protein in non-small cell lung cancer NSCLC and investigate its correlation with clinicopathologic features and prognosis.


Immunohistochemical staining was used to determine the expression of THOP1 protein in 120 NSCLC specimens and 53 distant normal lung tissues. Quantitative real-time PCR and western blotting were employed to measure the expression of THOP1 in 16 pairs of primary NSCLC and corresponding normal tissues.


Analysis of immunohistochemical staining suggested low THOP1 expression was found in 71 59.2% of the 120 NSCLC specimens and significantly correlated with positive lymph node metastasis P = 0.048. However, low THOP1 expression was found in 22 41.5% of the 53 normal lung tissues. Chi-square test suggested that the expression of THOP1 was significantly higher in the normal lung tissues than that in the NSCLC specimens P = 0.032. Real-Time PCR and western blotting showed that NSCLC specimens had decreased THOP1 mRNA and protein expression compared to corresponding normal tissues. Univariate analysis demonstrated that low THOP1 expression significantly predicted decreased 5-year disease-free survival P = 0.038 and overall survival P = 0.017. In addition, positive lymph node metastasis P = 0.025 and advanced TNM stage P = 0.009 significantly predicted decreased 5-year overall survival. However, multivariate Cox regression analysis showed that only low THOP1 expression retained its significance as an independent prognostic factor for unfavorable 5-year disease-free survival P = 0.046 and overall survival P = 0.021.


THOP1 may have clinical potentials to be employed as a promising biomarker to identify individuals with better prognosis and a novel antitumor agent for therapy of patients with NSCLC.

Autor: Lei Qi, Shu-hai Li, Li-bo Si, Ming Lu, Hui Tian



Documentos relacionados